Reactive vaccination in the presence of disease hotspots

Proceedings of the Royal Society B: Biological Sciences

Volumn 282, Issue 1798, 2014, Pages

  Azman, Andrew S ^a   Lessler, Justin ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cholera; Communicable disease control; Epidemiology; Infectious disease transmission; Outbreak response; Reactive vaccination

Indexed keywords

CHOLERA VACCINE; DRUG ADMINISTRATION;

CHOLERA; DISEASE CONTROL; DISEASE TRANSMISSION; HEALTH SERVICES; INFECTIOUS DISEASE; VACCINATION;

BIOLOGICAL MODEL; CHOLERA; EPIDEMICS; EPIDEMIOLOGY; HUMAN; MASS IMMUNIZATION; PREVENTION; PROCEDURES; TRANSMISSION;

ADMINISTRATION AND DOSAGE; CHOLERA; CHOLERA VACCINES; EPIDEMICS; EPIDEMIOLOGY; HUMANS; MASS VACCINATION; METHODS; MODELS, BIOLOGICAL; PREVENTION AND CONTROL; TRANSMISSION;

EID: 84910614248     PISSN: 09628452     EISSN: 14712954     Source Type: Journal    
DOI: 10.1098/rspb.2014.1341     Document Type: Article

References (36)

1. Grais RF, Conlan AJK, Ferrari MJ, Djibo A, Le Menach A, Bjornstad ON, Grenfell BT. 2008 Time is of the essence: exploring a measles outbreak response vaccination in Niamey, Niger. J. R. Soc. Interface 5, 67–74. (doi:10.1098/rsif.2007.1038)
2. Alberti KP, King LA, Burny ME, Ilunga BK, Grais RF. 2010 Reactive vaccination as an effective tool for measles outbreak control in measles mortality reduction settings, Democratic Republic of Congo, 2005–2006. Int. Health 2, 65–68. (doi:10.1016/j. inhe.2009.12.009)
3. Tildesley MJ, Savill NJ, Shaw DJ, Deardon R, Brooks SP, Woolhouse MEJ, Grenfell BT, Keeling MJ. 2006 Optimal reactive vaccination strategies for a footand- mouth outbreak in the UK. Nature 440, 83–86. (doi:10.1038/nature04324)
4. Ciglenecki I, Luquero FJ, Sakoba K, Heile M, Itama C. 2013 PLoS medicine: feasibility of mass vaccination campaign with oral cholera vaccines in response to an outbreak in Guinea. PLoS Med. 10, e1001512. (doi:10.1371/journal.pmed.1001512)
5. Azman AS, Luquero FJ, Rodrigues A, Palma PP, Grais RF, Banga CN, Grenfell BT, Lessler J. 2012 Urban cholera transmission hotspots and their implications for reactive vaccination: evidence from Bissau City, Guinea Bissau. PLoS Negl. Trop. Dis. 6, e1901. (doi:10.1371/journal.pntd.0001901)
6. Bhattacharya SK et al. 2013 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect. Dis. 13, 1050–1056. (doi:10.1016/S1473-3099(13)70273-1)
7. van Loon FPL et al. 1996 Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. Vaccine 14, 162–166. (doi:10.1016/0264-410X(95)00122-H)
8. World Health Organization. 2013 Cholera, 2012. Wkly Epidemiol. Rec. 88, 321–334.
9. Ali M, Lopez AL, You YA, Kim YE, Sah B, Maskery B, Clemens J. 2012 The global burden of cholera. Bull. World Health Organ. 90, 209–218. (doi:10.2471/ BLT.11.093427)
10. World Health Organization. 2013 Guidance on how to access the oral cholera vaccine (OCV) from the ICG emergency stockpile. Geneva, Switzerland: World Health Organization.
11. Rebaudet S, Sudre B, Faucher B, Piarroux R. 2013 Environmental determinants of cholera outbreaks in inland Africa: a systematic review of main transmission foci and propagation routes. J. Infect. Dis. 208(Suppl. 1), S46–S54. (doi:10.1093/infdis/jit195)
12. Mukandavire Z, Smith DL, Morris JG. 2013 Cholera in Haiti: reproductive numbers and vaccination coverage estimates. Sci. Rep. 3, 997. (doi:10.1038/srep00997)
13. Dowdy DW, Golub JE, Chaisson RE, Saraceni V. 2012 Heterogeneity in tuberculosis transmission and the role of geographic hotspots in propagating epidemics. Proc. Natl Acad. Sci. USA 109, 9557–9562. (doi:10.1073/pnas.1203517109)
14. Keeling MJ, White PJ. 2011 Targeting vaccination against novel infections: risk, age and spatial structure for pandemic influenza in Great Britain. J. R. Soc. Interface 8, 661–670. (doi:10.1098/rsif. 2010.0474)
15. Keeling MJ, Shattock A. 2012 Optimal but unequitable prophylactic distribution of vaccine. Epidemics 4, 78–85. (doi:10.1016/j.epidem.2012.03.001)
16. Wesolowski A, Eagle N, Tatem AJ, Smith DL, Noor AM, Snow RW, Buckee CO. 2012 Quantifying the impact of human mobility on malaria. Science 338, 267–270. (doi:10.1126/science.1223467)
17. Bharti N, Djibo A, Djibo A, Ferrari MJ, Grais RF, Tatem AJ, McCabe CA, Bjornstad ON, Grenfell BT. 2010 Measles hotspots and epidemiological connectivity. Epidemiol. Infect. 138, 1308–1316. (doi:10.1017/S0950268809991385)
18. Chao DL, Halloran ME, Longini IM. 2011 Vaccination strategies for epidemic cholera in Haiti with implications for the developing world. Proc. Natl Acad. Sci. USA 108, 7081–7085. (doi:10.1073/pnas. 1102149108)
19. Mari L, Bertuzzo E, Righetto L, Casagrandi R, Gatto M, Rodriguez-Iturbe I, Rinaldo A. 2012 Modelling cholera epidemics: the role of waterways, human mobility and sanitation. J. R. Soc. Interface 9, 376–388. (doi:10.1098/rsif.2011.0304)
20. Wu JT, Riley S, Fraser C, Leung GM. 2007 Spatial considerations for the allocation of pre-pandemic influenza vaccination in the United States. Proc. R. Soc. B 274, 2811–2817. (doi:10.1098/rspb. 2007.0893)
21. Matrajt L, Halloran ME, Longini IM. 2013 Optimal vaccine allocation for the early mitigation of pandemic influenza. PLoS Comput. Biol. 9, e1002964. (doi:10.1371/journal.pcbi.1002964)
22. Araz OM, Galvani A, Meyers LA. 2012 Geographic prioritization of distributing pandemic influenza vaccines. Health Care Manage. Sci. 15, 175–187. (doi:10.1007/s10729-012-9199-6)
23. Weil AA, Khan AI, Chowdhury F, LaRocque RC, Faruque ASG, Ryan ET, Calderwood SB, Qadri F, Harris JB. 2009 Clinical outcomes in household contacts of patients with cholera in Bangladesh. Clin. Infect. Dis. 49, 1473–1479. (doi:10.1086/644779)
24. Halloran ME, Longini IM, Struchiner CJ. 2009 Design and analysis of vaccine studies. Berlin, Germany: Springer.
25. Diekmann O, Heesterbeek JAP, Roberts MG. 2010 The construction of next-generation matrices for compartmental epidemic models. J. R. Soc. Interface 7, 873–885. (doi:10.1098/rsif.2009.0386)
26. Mukandavire Z, Liao S, Wang J, Gaff H, Smith DL, Morris JG. 2011 Estimating the reproductive numbers for the 2008–2009 cholera outbreaks in Zimbabwe. Proc. Natl Acad. Sci. USA 108, 8767–8772. (doi:10.1073/pnas.1019712108)
27. King AA, Ionides EL, Pascual M, Bouma MJ. 2008 Inapparent infections and cholera dynamics. Nature 454, 877–880. (doi:10.1038/nature07084)
28. Longini IM, Ackerman E, Elveback LR. 1978 An optimization model for influenza A epidemics. Math. Biosci. 38, 141–157. (doi:10.1016/0025- 5564(78)90023-8)
29. Ma J, Earn DJD. 2006 Generality of the final size formula for an epidemic of a newly invading infectious disease. Bull. Math Biol. 68, 679–702. (doi:10.1007/s11538-005-9047-7)
30. Team RDC. 2011 R: a language and environment for statistical computing. Vienna, Austria: Team RDC.
31. Jones E et al. SciPy: open source scientific tools for PYTHON. See http://www.scipy.org/.
32. Anderson RM, May RM. 1992 Infectious diseases of humans: dynamics and control. Oxford, UK: Oxford University Press.
33. Kanungo S, Paisley A, Lopez AL, Bhattacharya M. 2009 Immune responses following one and two doses of the reformulated, bivalent, killed, wholecell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial. Vaccine 27, 6887–6893. (doi:10.1016/j. vaccine.2009.09.008)
34. Klepac P, Laxminarayan R, Grenfell BT. 2011 Synthesizing epidemiological and economic optima for control of immunizing infections. Proc. Natl Acad. Sci. USA 108, 14366–14370. (doi:10.1073/ pnas.1101694108)
35. Wallinga J, van Boven M, Lipsitch M. 2010 Optimizing infectious disease interventions during an emerging epidemic. Proc. Natl Acad. Sci. USA 107, 923–928. (doi:10.1073/pnas.0908491107)
36. Hens N, Van Ranst M, Aerts M, Robesyn E, Van Damme P, Beutels P. 2011 Estimating the effective reproduction number for pandemic influenza from notification data made publicly available in real time: a multi-country analysis 445 for influenza A/ H1N1v 2009. Vaccine 29, 896–904. (doi:10.1016/j. vaccine.2010.05.010)